655 related articles for article (PubMed ID: 3319120)
1. A comparison of bromocriptine (Parlodel) and levodopa-carbidopa (Sinemet) for treatment of "de novo" Parkinson's disease patients.
Libman I; Gawel MJ; Riopelle RJ; Bouchard S
Can J Neurol Sci; 1987 Nov; 14(4):576-80. PubMed ID: 3319120
[TBL] [Abstract][Full Text] [Related]
2. Bromocriptine in the treatment of Parkinson's disease: a double-blind study against L-dopa/carbidopa.
Gawel M; Riopelle R; Libman I; Bouchard S
Adv Neurol; 1987; 45():535-8. PubMed ID: 3548263
[No Abstract] [Full Text] [Related]
3. Levodopa + carbidopa + entacapone. Entacapone: a second look: new preparations. Parkinson's disease: a modest effect.
Prescrire Int; 2005 Apr; 14(76):51-4. PubMed ID: 15875340
[TBL] [Abstract][Full Text] [Related]
4. Multicenter controlled study of Sinemet CR vs Sinemet (25/100) in advanced Parkinson's disease.
Hutton JT; Morris JL; Bush DF; Smith ME; Liss CL; Reines S
Neurology; 1989 Nov; 39(11 Suppl 2):67-72; discussion 72-3. PubMed ID: 2685652
[TBL] [Abstract][Full Text] [Related]
5. The effect of deprenyl and levodopa on the progression of Parkinson's disease.
Olanow CW; Hauser RA; Gauger L; Malapira T; Koller W; Hubble J; Bushenbark K; Lilienfeld D; Esterlitz J
Ann Neurol; 1995 Nov; 38(5):771-7. PubMed ID: 7486869
[TBL] [Abstract][Full Text] [Related]
6. Time course of loss of clinical benefit following withdrawal of levodopa/carbidopa and bromocriptine in early Parkinson' s disease.
Hauser RA; Koller WC; Hubble JP; Malapira T; Busenbark K; Olanow CW
Mov Disord; 2000 May; 15(3):485-9. PubMed ID: 10830413
[TBL] [Abstract][Full Text] [Related]
7. A double-blind study of bromocriptine and L-dopa in de novo Parkinson's disease. Short-term results.
Riopelle RJ; Gawel MJ; Libman I; King DB; McLean DR; Paulseth R; Raphy B; Bouchard S
Eur Neurol; 1988; 28 Suppl 1():11-4. PubMed ID: 3288477
[TBL] [Abstract][Full Text] [Related]
8. Low-dosage treatment in de novo patients with Parkinson's disease: a prospective study.
van der Drift JH
Adv Neurol; 1987; 45():529-34. PubMed ID: 3825731
[TBL] [Abstract][Full Text] [Related]
9. The Sydney multicentre study of Parkinson's disease. The first 18 months.
Hely MA; Morris JG; Rail D; O'Sullivan DJ; Williamson PM; Genge S; Reid WG; Broe GA
Med J Aust; 1987 Feb; 146(4):195-8. PubMed ID: 3553878
[TBL] [Abstract][Full Text] [Related]
10. Pharmacotherapy: problems and practices.
Muenter MD
Clin Neuropharmacol; 1986; 9 Suppl 1():S23-36. PubMed ID: 3708606
[TBL] [Abstract][Full Text] [Related]
11. Comparative study of selegiline plus L-dopa-carbidopa versus L-dopa-carbidopa alone in the treatment of Parkinson's disease.
Brannan T; Yahr MD
Ann Neurol; 1995 Jan; 37(1):95-8. PubMed ID: 7818264
[TBL] [Abstract][Full Text] [Related]
12. [Treatment of Parkinson's disease with the combination drug L-carbidopa/L-dopa. Report on a 2 years study].
Hayek J
Schweiz Med Wochenschr; 1977 Apr; 107(14):474-9. PubMed ID: 847450
[TBL] [Abstract][Full Text] [Related]
13. Double-blind controlled study of pergolide mesylate as an adjunct to Sinemet in the treatment of Parkinson's disease.
Olanow CW; Alberts MJ
Adv Neurol; 1987; 45():555-60. PubMed ID: 3548266
[No Abstract] [Full Text] [Related]
14. Superior clinical efficacy of Sinement CR 50/200 versus Sinemet 25/100 in patients with fluctuating Parkinson's disease. An open and a double-blind, double-dummy, multicenter treatment evaluation. Dutch Sinement CR Study Group.
Wolters EC; Horstink MW; Roos RA; Jansen EN
Adv Neurol; 1993; 60():648-52. PubMed ID: 8420204
[No Abstract] [Full Text] [Related]
15. Risk factors for motor response complications in L-dopa-treated parkinsonian patients.
Peppe A; Dambrosia JM; Chase TN
Adv Neurol; 1993; 60():698-702. PubMed ID: 8420213
[No Abstract] [Full Text] [Related]
16. [Pharmacokinetic comparison of Sinemet and Grifoparkin (levodopa/carbidopa 250/25 mg) in Parkinson s disease: a single dose study].
Chaná P; Fierro A; Reyes-Parada M; Sáez-Briones P
Rev Med Chil; 2003 Jun; 131(6):623-31. PubMed ID: 12942590
[TBL] [Abstract][Full Text] [Related]
17. Sinemet CR in Parkinson's disease.
Pfeiffer RF; Wilken KE; Glaeske CS; Hofman R
Nebr Med J; 1991 Jan; 76(1):8-10. PubMed ID: 1997878
[TBL] [Abstract][Full Text] [Related]
18. Concurrent administration of donepezil HCl and levodopa/carbidopa in patients with Parkinson's disease: assessment of pharmacokinetic changes and safety following multiple oral doses.
Okereke CS; Kirby L; Kumar D; Cullen EI; Pratt RD; Hahne WA
Br J Clin Pharmacol; 2004 Nov; 58 Suppl 1(Suppl 1):41-9. PubMed ID: 15496222
[TBL] [Abstract][Full Text] [Related]
19. Controlled-release levodopa/carbidopa. III: Sinemet CR5 treatment of response fluctuations in Parkinson's disease.
Cedarbaum JM; Hoey M; Kutt H; McDowell FH
Clin Neuropharmacol; 1988 Apr; 11(2):168-73. PubMed ID: 3378225
[TBL] [Abstract][Full Text] [Related]
20. [Bromocriptine in Parkinsonian syndromes. Results obtained in a group of patients treated for 8 months].
Quattrini A; Paggi A; Del Pesce M; Di Bella P
Riv Patol Nerv Ment; 1978; 99(3):150-63. PubMed ID: 752907
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
